[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
April 17, 2002

Is One Selective Serotonin Reuptake Inhibitor Better Than Another?

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(15):1935-1938. doi:10.1001/jama.287.15.1935

To the Editor: Considering that Eli Lilly sponsored the trial by Dr Kroenke and colleagues1 and that their product, fluoxetine, was the least efficacious of the 3 selective serotonin reuptake inhibitors (SSRIs) evaluated, I am not surprised that the authors emphasized that all 3 were similarly effective. In fact, the authors proclaim that the "ARTIST results unequivocally demonstrate the lack of differences among 3 SSRIs across a broad range of outcomes over 9 months." The results are anything but unequivocal.

First Page Preview View Large
First page PDF preview
First page PDF preview
×